$154 Million is the total value of Iguana Healthcare Management, LLC's 61 reported holdings in Q4 2017. The portfolio turnover from Q3 2017 to Q4 2017 was 60.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ESPR | Sell | ESPERION THERAPEUTICS INC NE | $10,864,000 | -27.7% | 165,000 | -45.0% | 7.08% | +70.6% |
| CELG | Sell | CELGENE CORP | $7,827,000 | -64.2% | 75,000 | -50.0% | 5.10% | -15.5% |
| IMMU | Sell | IMMUNOMEDICS INC | $7,272,000 | -48.0% | 450,000 | -55.0% | 4.74% | +22.9% |
| BIIB | Sell | BIOGEN INC | $7,009,000 | -44.0% | 22,000 | -45.0% | 4.56% | +32.2% |
| HUM | New | HUMANA INC | $5,582,000 | – | 22,500 | +100.0% | 3.64% | – |
| AERI | Sell | AERIE PHARMACEUTICALS INC | $5,079,000 | -47.7% | 85,000 | -57.5% | 3.31% | +23.4% |
| CI | Sell | CIGNA CORPORATION | $5,077,000 | -48.8% | 25,000 | -52.8% | 3.31% | +21.0% |
| GBT | Sell | GLOBAL BLOOD THERAPEUTICS IN | $4,919,000 | -36.6% | 125,000 | -50.0% | 3.20% | +49.7% |
| ABBV | Sell | ABBVIE INC | $4,836,000 | -58.1% | 50,000 | -61.5% | 3.15% | -1.1% |
| MRK | Sell | MERCK & CO INC | $4,502,000 | -53.1% | 80,000 | -46.7% | 2.93% | +10.7% |
| ABT | Sell | ABBOTT LABS | $4,280,000 | -52.8% | 75,000 | -55.9% | 2.79% | +11.4% |
| CLVS | Sell | CLOVIS ONCOLOGY INC | $4,080,000 | -69.1% | 60,000 | -62.5% | 2.66% | -26.9% |
| ANAB | Sell | ANAPTYSBIO INC | $4,029,000 | +15.2% | 40,000 | -60.0% | 2.62% | +172.2% |
| KTWO | Sell | K2M GROUP HLDGS INC | $3,150,000 | -62.9% | 175,000 | -56.2% | 2.05% | -12.3% |
| BMY | Sell | BRISTOL MYERS SQUIBB CO | $3,064,000 | -56.3% | 50,000 | -54.5% | 2.00% | +3.2% |
| SRRA | Sell | SIERRA ONCOLOGY INC | $2,984,000 | +60.4% | 800,000 | -33.3% | 1.94% | +278.8% |
| TSRO | Sell | TESARO INC | $2,900,000 | -55.1% | 35,000 | -30.0% | 1.89% | +6.1% |
| KPTI | Sell | KARYOPHARM THERAPEUTICS INC | $2,880,000 | -67.2% | 300,000 | -62.5% | 1.88% | -22.5% |
| DERM | Sell | DERMIRA INC | $2,781,000 | -58.8% | 100,000 | -60.0% | 1.81% | -2.7% |
| JUNO | Sell | JUNO THERAPEUTICS INC | $2,743,000 | -59.2% | 60,000 | -60.0% | 1.79% | -3.8% |
| ZBH | Sell | ZIMMER BIOMET HLDGS INC | $2,715,000 | -61.4% | 22,500 | -62.5% | 1.77% | -8.7% |
| SGMO | Sell | SANGAMO THERAPEUTICS INC | $2,460,000 | -59.0% | 150,000 | -62.5% | 1.60% | -3.1% |
| XENT | Sell | INTERSECT ENT INC | $2,430,000 | -56.7% | 75,000 | -58.3% | 1.58% | +2.4% |
| DHR | Sell | DANAHER CORP DEL | $2,321,000 | -61.3% | 25,000 | -64.3% | 1.51% | -8.6% |
| RARE | Sell | ULTRAGENYX PHARMACEUTICAL IN | $2,319,000 | -56.5% | 50,000 | -50.0% | 1.51% | +2.8% |
| MYOK | New | MYOKARDIA INC | $2,105,000 | – | 50,000 | +100.0% | 1.37% | – |
| IONS | Buy | IONIS PHARMACEUTICALS INC | $2,012,000 | +32.2% | 40,000 | +33.3% | 1.31% | +211.9% |
| SUPN | New | SUPERNUS PHARMACEUTICALS INC | $1,993,000 | – | 50,000 | +100.0% | 1.30% | – |
| MRUS | Sell | MERUS N V | $1,940,000 | -30.3% | 100,000 | -28.6% | 1.26% | +64.7% |
| ADMA | Sell | ADMA BIOLOGICS INC | $1,926,000 | -44.7% | 600,000 | -46.9% | 1.25% | +30.6% |
| PFE | Sell | PFIZER INC | $1,811,000 | -57.7% | 50,000 | -58.3% | 1.18% | -0.2% |
| WVE | Sell | WAVE LIFE SCIENCES LTD | $1,755,000 | -26.6% | 50,000 | -54.5% | 1.14% | +73.2% |
| AKCA | New | AKCEA THERAPEUTICS INC | $1,736,000 | – | 100,000 | +100.0% | 1.13% | – |
| PBYI | New | PUMA BIOTECHNOLOGY INC | $1,730,000 | – | 17,500 | +100.0% | 1.13% | – |
| Sell | CLOVIS ONCOLOGY INCcall | $1,700,000 | -86.2% | 25,000 | -83.3% | 1.11% | -67.5% | |
| ARNA | Sell | ARENA PHARMACEUTICALS INC | $1,699,000 | -44.5% | 50,000 | -58.3% | 1.11% | +31.0% |
| MYL | New | MYLAN N V | $1,692,000 | – | 40,000 | +100.0% | 1.10% | – |
| AVXS | Sell | AVEXIS INC | $1,660,000 | -51.0% | 15,000 | -57.1% | 1.08% | +15.7% |
| MDCO | Sell | MEDICINES CO | $1,640,000 | -77.9% | 60,000 | -70.0% | 1.07% | -47.7% |
| AGN | New | ALLERGAN PLC | $1,636,000 | – | 10,000 | +100.0% | 1.06% | – |
| ABLX | New | ABLYNX NVsponsored adr | $1,617,000 | – | 65,000 | +100.0% | 1.05% | – |
| CTMX | Sell | CYTOMX THERAPEUTICS INC | $1,583,000 | -37.8% | 75,000 | -46.4% | 1.03% | +47.1% |
| BSX | Sell | BOSTON SCIENTIFIC CORP | $1,240,000 | -83.0% | 50,000 | -80.0% | 0.81% | -59.8% |
| CTLT | CATALENT INC | $1,232,000 | +2.8% | 30,000 | 0.0% | 0.80% | +143.0% | |
| GSK | New | GLAXOSMITHKLINE PLCsponsored adr | $1,064,000 | – | 30,000 | +100.0% | 0.69% | – |
| DPLO | Sell | DIPLOMAT PHARMACY INC | $1,004,000 | -59.6% | 50,000 | -58.3% | 0.65% | -4.5% |
| RGNX | New | REGENXBIO INC | $998,000 | – | 30,000 | +100.0% | 0.65% | – |
| INCY | New | INCYTE CORP | $947,000 | – | 10,000 | +100.0% | 0.62% | – |
| LHCG | New | LHC GROUP INC | $919,000 | – | 15,000 | +100.0% | 0.60% | – |
| VKTX | New | VIKING THERAPEUTICS INC | $913,000 | – | 225,000 | +100.0% | 0.60% | – |
| CORI | Sell | CORIUM INTL INC | $865,000 | -68.8% | 90,000 | -64.0% | 0.56% | -26.3% |
| VYGR | VOYAGER THERAPEUTICS INC | $830,000 | -19.4% | 50,000 | 0.0% | 0.54% | +90.5% | |
| MRNS | Sell | MARINUS PHARMACEUTICALS INC | $816,000 | -60.3% | 100,000 | -71.4% | 0.53% | -6.2% |
| AKAOQ | Buy | ACHAOGEN INC | $806,000 | -15.9% | 75,000 | +25.0% | 0.52% | +98.9% |
| ADVM | New | ADVERUM BIOTECHNOLOGIES INC | $700,000 | – | 200,000 | +100.0% | 0.46% | – |
| OMED | Sell | ONCOMED PHARMACEUTICALS INC | $615,000 | -80.6% | 150,000 | -78.6% | 0.40% | -54.0% |
| CCXI | Sell | CHEMOCENTRYX INC | $595,000 | -85.4% | 100,000 | -81.8% | 0.39% | -65.6% |
| SCYX | Sell | SCYNEXIS INC | $580,000 | -51.9% | 250,000 | -50.0% | 0.38% | +13.5% |
| WMGI | New | WRIGHT MED GROUP N V | $444,000 | – | 20,000 | +100.0% | 0.29% | – |
| New | NEWLINK GENETICS CORPcall | $406,000 | – | 50,000 | +100.0% | 0.26% | – | |
| TRXC | New | TRANSENTERIX INC | $241,000 | – | 125,000 | +100.0% | 0.16% | – |
| OBSV | Exit | OBSEVA SA | $0 | – | -50,000 | -100.0% | -0.11% | – |
| ADAP | Exit | ADAPTIMMUNE THERAPEUTICS PLCsponds adr | $0 | – | -50,000 | -100.0% | -0.11% | – |
| Exit | IGNYTA INCcall | $0 | – | -50,000 | -100.0% | -0.17% | – | |
| Exit | PTC THERAPEUTICS INCcall | $0 | – | -50,000 | -100.0% | -0.28% | – | |
| Exit | EXELIXIS INCput | $0 | – | -50,000 | -100.0% | -0.33% | – | |
| Exit | NEOVASC INC | $0 | – | -720,000 | -100.0% | -0.34% | – | |
| ZGNX | Exit | ZOGENIX INC | $0 | – | -40,000 | -100.0% | -0.39% | – |
| Exit | INCYTE CORPcall | $0 | – | -15,000 | -100.0% | -0.48% | – | |
| PRTK | Exit | PARATEK PHARMACEUTICALS INC | $0 | – | -70,000 | -100.0% | -0.48% | – |
| FOLD | Exit | AMICUS THERAPEUTICS INC | $0 | – | -120,000 | -100.0% | -0.50% | – |
| ASND | Exit | ASCENDIS PHARMA A Ssponsored adr | $0 | – | -60,000 | -100.0% | -0.60% | – |
| TDOC | Exit | TELADOC INC | $0 | – | -70,000 | -100.0% | -0.64% | – |
| KURA | Exit | KURA ONCOLOGY INC | $0 | – | -180,000 | -100.0% | -0.74% | – |
| RXDX | Exit | IGNYTA INC | $0 | – | -250,000 | -100.0% | -0.85% | – |
| INSM | Exit | INSMED INC | $0 | – | -100,000 | -100.0% | -0.86% | – |
| ESRX | Exit | EXPRESS SCRIPTS HLDG CO | $0 | – | -50,000 | -100.0% | -0.87% | – |
| CAH | Exit | CARDINAL HEALTH INC | $0 | – | -60,000 | -100.0% | -1.11% | – |
| CBAY | Exit | CYMABAY THERAPEUTICS INC | $0 | – | -500,000 | -100.0% | -1.11% | – |
| FGEN | Exit | FIBROGEN INC | $0 | – | -80,000 | -100.0% | -1.19% | – |
| XLRN | Exit | ACCELERON PHARMA INC | $0 | – | -140,000 | -100.0% | -1.44% | – |
| GKOS | Exit | GLAUKOS CORP | $0 | – | -200,000 | -100.0% | -1.82% | – |
| LLY | Exit | LILLY ELI & CO | $0 | – | -80,000 | -100.0% | -1.89% | – |
| AET | Exit | AETNA INC NEW | $0 | – | -57,000 | -100.0% | -2.50% | – |
| ALXN | Exit | ALEXION PHARMACEUTICALS INC | $0 | – | -80,000 | -100.0% | -3.10% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| BIOGEN INC | 17 | Q1 2018 | 7.5% |
| ULTRAGENYX PHARMACEUTICAL IN | 17 | Q1 2018 | 6.7% |
| MERCK & CO INC NEW | 16 | Q1 2018 | 5.4% |
| CELGENE CORP | 15 | Q4 2017 | 7.9% |
| AERIE PHARMACEUTICALS INC | 15 | Q4 2017 | 3.3% |
| GILEAD SCIENCES INC | 14 | Q1 2017 | 6.7% |
| ESPERION THERAPEUTICS INC NE | 14 | Q1 2018 | 7.8% |
| SUPERNUS PHARMACEUTICALS INC | 14 | Q4 2017 | 2.8% |
| DERMIRA INC | 14 | Q1 2018 | 2.7% |
| AMGEN INC | 13 | Q1 2017 | 6.5% |
View Iguana Healthcare Management, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2018-05-15 |
| 13F-HR | 2018-02-14 |
| 13F-HR/A | 2017-11-16 |
| 13F-HR | 2017-11-14 |
| 13F-HR | 2017-08-14 |
| 13F-HR | 2017-05-15 |
| 13F-HR | 2017-02-14 |
| 13F-HR/A | 2016-11-17 |
| 13F-HR | 2016-11-14 |
| 13F-HR/A | 2016-11-04 |
View Iguana Healthcare Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.